Product Program year 2025 Source: CMS Open Payments

Aldurazyme

Biological Genetic Disease

NDC 58468-0070-1

Open in the dashboard

General payments

$90,147

216 payments

Research payments

$300,906

105 payments

Through program year 2025, $90,147 in general payments and $300,906 in research payments were reported against Aldurazyme (Genetic Disease).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

12 rows
Year Kind Amount Payments
2025 General $1,776 58
2025 Research $12,939 13
2024 General $22,215 47
2024 Research $34,941 29
2023 General $10,991 46
2023 Research $231,036 55
2022 General $29,619 40
2021 General $13,827 11
2021 Research $14,724 1
2020 General $11,596 13
2020 Research $7,267 7
2019 General $122 1

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $47,573 13 payments
  2. Genzyme Corporation $42,575 203 payments
Top recipients General payments · program year 2025
  1. Joshua Baker Clinical Genetics (M.D.) · Chicago, IL $151 9% · 1 payment
  2. Carlos Prada Clinical Genetics (M.D.) · Chicago, IL $151 9% · 1 payment
  3. Mickey Kuo Clinical Genetics (M.D.) · Bethesda, MD $151 9% · 1 payment
  4. Michelle Tharp Nurse Practitioner · Jackson, MS $46 3% · 2 payments
  5. Paulo Borjas Mendoza Jackson, MS $46 3% · 2 payments

The top 5 of 55 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Clinical Genetics (M.D.) Medical Genetics $535 31% · 7 practitioners
  2. Pediatrics $271 16% · 11 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $164 10% · 7 practitioners
  4. Ophthalmology $127 7% · 4 practitioners
  5. Nurse Practitioner $108 6% · 4 practitioners

The top 5 of 20 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Illinois $453 26% · 3 recipients
  2. South Carolina $220 12% · 9 recipients
  3. Alabama $180 10% · 10 recipients
  4. Texas $178 10% · 7 recipients
  5. Florida $132 7% · 4 recipients

The top 5 of 16 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

134

Prescriptions dispensed, refills included

Drug cost

$5,785,194

Paid at the pharmacy, in all

Prescribers

7

With 11 or more claims of it

Medicare Part D drugs matched to ALDURAZYME, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Aldurazyme Laronidase Same name 7 134 $5,785,194

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 7 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Annabelle Wilcox Physician Assistant UT 50 $1,547,608 None on record
Lisa Jenike Nurse Practitioner MA 24 $1,567,551 None on record
Janet Thomas Medical Genetics and Genomics CO 13 $507,454 None on record
Laura Buch Physician Assistant SC 12 $669,353 None on record
Mari Mori Medical Genetics and Genomics OH 12 $602,763 $11

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 7 in the dashboard with a free account
216 general · 105 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record